share_log

Berry GenomicsLtd (SZSE:000710 Investor Three-year Losses Grow to 84% as the Stock Sheds CN¥661m This Past Week

Berry GenomicsLtd (SZSE:000710 Investor Three-year Losses Grow to 84% as the Stock Sheds CN¥661m This Past Week

Berry GenomicsLtd(深圳证券交易所股票代码:000710)上周股价下跌6.61亿元人民币,投资者三年期亏损增至84%
Simply Wall St ·  02/08 19:28

As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So consider, for a moment, the misfortune of Berry Genomics Co.,Ltd (SZSE:000710) investors who have held the stock for three years as it declined a whopping 84%. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it mildly. And more recent buyers are having a tough time too, with a drop of 53% in the last year. Even worse, it's down 42% in about a month, which isn't fun at all. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

作为投资者,错误是不可避免的。但是,真正的巨额亏损确实会拖累整个投资组合。因此,请暂时考虑一下贝瑞基因组公司的不幸。, Ltd(深圳证券交易所股票代码:000710)投资者已持有该股三年,该股跌幅高达84%。客气地说,这可能会使人们严重怀疑最初购买该股票的决定的优点。最近的买家也遇到了艰难时期,去年下降了53%。更糟糕的是,它在大约一个月内下降了42%,这一点都不好玩。在这种情况下,我们真的对股东有同感。这很好地提醒了多元化的重要性,无论如何,值得记住的是,生活中存在的不仅仅是金钱。

Since Berry GenomicsLtd has shed CN¥661m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由于Berry GenomicsLtd在过去7天内已从其市值下跌了6.61亿元人民币,因此让我们看看长期下跌是否是由该公司的经济推动的。

Given that Berry GenomicsLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

鉴于Berry GenomicsLtd在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。一般而言,没有利润的公司预计每年收入将增长,而且速度很快。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。

Over the last three years, Berry GenomicsLtd's revenue dropped 8.2% per year. That's not what investors generally want to see. Having said that the 23% annualized share price decline highlights the risk of investing in unprofitable companies. This business clearly needs to grow revenues if it is to perform as investors hope. Don't let a share price decline ruin your calm. You make better decisions when you're calm.

在过去的三年中,Berry GenomicsLtd的收入每年下降8.2%。这不是投资者普遍希望看到的。话虽如此,年化股价下跌23%凸显了投资无利可图公司的风险。该业务要想如投资者所希望的那样表现,显然需要增加收入。不要让股价下跌破坏你的平静。当你冷静时,你会做出更好的决定。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
SZSE:000710 Earnings and Revenue Growth February 9th 2024
SZSE: 000710 收益和收入增长 2024 年 2 月 9 日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在这张免费的交互式图片中看到其资产负债表如何随着时间的推移而增强(或减弱)。

A Different Perspective

不同的视角

We regret to report that Berry GenomicsLtd shareholders are down 53% for the year. Unfortunately, that's worse than the broader market decline of 23%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 13% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Berry GenomicsLtd , and understanding them should be part of your investment process.

我们遗憾地向大家报告,Berry GenomicsLtd的股东今年下跌了53%。不幸的是,这比整个市场23%的跌幅还要严重。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中13%的年化亏损还要糟糕。我们意识到罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。例如,以永远存在的投资风险幽灵为例。我们已经向Berry GenomicsLtd确定了两个警告信号,了解它们应该是您投资过程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发